Therapeutic mechanisms of psychedelics and entactogens

Summary & key facts

This paper reviews human and animal research on so-called psychedelics (like psilocybin and LSD) and entactogens (mainly MDMA). The authors say these drugs can produce fast improvements in mental health that sometimes last for months or longer. But we do not yet understand exactly how they work. Human studies point to the importance of the drug experience and the therapeutic setting, while animal studies look at brain cells and connections. The review argues we should study which brain circuits these drugs change, and it warns about limits like addiction risk, side effects, and problems scaling these treatments to many people.

Key facts:

• Clinical trials show that a single or a few doses of drugs such as MDMA and psilocybin can give people benefits that last for months and possibly years, but we do not fully know why these benefits happen.
• Human research emphasizes non-drug factors called "set, setting, and integration" — meaning a person’s mindset, the physical and social environment, and follow-up therapy — and these factors are hard to model in animal studies.
• Animal studies focus on changes in brain activity and on structural plasticity, which means changes in how brain cells connect to each other. Those changes are difficult to measure directly in people.
• Classical psychedelics like LSD and psilocybin mainly act on a brain receptor called serotonin 2A and often change perception and thinking (for example, causing hallucinations).
• Entactogens such as MDMA mainly cause the brain to release serotonin and tend to increase social openness and memory retrieval, without the classic hallucinations of psychedelics.
• Because these drugs act in many different ways at the molecular level, the authors suggest their lasting effects may be better explained by which brain circuits they influence, not by any single chemical target.
• The review points out real-world limits: MDMA has known potential for misuse and long-term neurological and cardiovascular risks, and both MDMA and psilocybin face challenges for wide use because of cost, complexity of therapy, and how to f
• The authors call for better ways to connect human clinical results and animal experiments so researchers can find safer, more scalable medicines that keep the fast and lasting benefits without unnecessary harms.

Topics

Biochemical Analysis and Sensing Techniques Neurotransmitter Receptor Influence on Behavior Psychedelics and Drug Studies

Categories

Clinical Psychology Psychology Social Sciences

Tags

Disease Human studies Internal medicine Medicine Neuronal circuits Neuroscience Pathology Psychology Therapeutic approach

Substances

Ketamine LSD MDMA Psilocybin

Conditions & symptoms

Depression PTSD Substance abuse disorder Anxiety or worry Feeling disconnected from others Sadness or low mood